Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2021 call → NOWe need to determine if management explains where the company's business is going by narrating what its counterparties are themselves doing and scaling. The question asks: does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company ALREADY SUPPLIES OR SERVES, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to look at the transcript. Management discusses sales growth, hiring sales reps, expanding territories, etc. They talk about Artegraft acquisition, XenoSure CE Mark issues, etc. They mention that they are growing sales force, maintaining margins, generating cash, investing in acquisitions. They talk about the impact of Delta variant on elective surgeries. They discuss guidance for Q4. Do they narrate what specific counterparties (like hospitals, distributors, etc.) are doing in terms of their own expansion? They mention that hospitals deferred elective surgery due to Delta, but that's a macro condition. They don't describe specific customers' own ramps or build-outs. They talk about their own sales force expansion, hiring reps, splitting territories. That's their own actions. They also mention that they are back to pre-COVID headcount. They talk about Artegraft sales growth, but that's their own product line. They don't describe a specific customer or partner scaling up. The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? The answer seems NO. They talk about their own efforts, market conditions, but not about specific counterparties' trajectories. They mention that they have 103 sales reps, hiring more, but that's their own expansion. They don't describe a hospital chain expanding, a distributor ramping, etc. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.